Literature DB >> 8269609

Proteinuria due to suboptimal hydration with high-dose methotrexate therapy.

G T Kovács1, C Paál, P Somló, R Koós, D Schuler, J D Borsi.   

Abstract

One of the major complications after high-dose methotrexate (HDMTX) infusions is renal damage. We investigated the occurrence of proteinuria after HDMTX administration in children with pediatric malignancies (acute lymphoid leukaemia, osteosarcoma Burkitt's lymphoma). In the period 1989-1990 we gave 52 HDMTX courses to 24 children. During this period, prehydration and extra urinary alkalisation were performed only if the urinary specific gravity was over 1010 or if the urinary pH fell below 7. Using this schedule the mean values obtained for protein extraction were: before the therapy, 0.12 +/- 0.03 g/m2; on day 1 after MTX treatment, 0.38 +/- 0.06 g/m2; and on day 2 after the MTX infusion, 0.39 +/- 0.11 g/m2 (P < 0.01). A significant increase in proteinuria (> 0.2 g/m2 post- vs pretreatment) was detectable in 54% of the patients. In the period 1991-1992 we modified the hydration-alkalisation schedule to include i.v. prehydration for 18-24 h at 3 l/m2/day with a 0.45% NaCl-5% glucose solution along with sodium bicarbonate and posthydration for 72 h with the same solution. On this protocol the mean values determined for the urinary protein content were all in the normal range (pretreatment, 0.03 g/m2/day; day 1, 0.05 g/m2/day; and day 2, 0.08 g/m2/day). These findings were significantly different from the previous results (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8269609     DOI: 10.1007/bf00686226

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

2.  Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.

Authors:  S W Pitman; E Frei
Journal:  Cancer Treat Rep       Date:  1977-07

3.  Severe renal toxicity due to intermediate-dose methotrexate.

Authors:  A N Stark; G Jackson; P J Carey; S Arfeen; S J Proctor
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.

Authors:  M L Christensen; G K Rivera; W R Crom; M L Hancock; W E Evans
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

5.  Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.

Authors:  J D Borsi; E Sagen; I Romslo; P J Moe
Journal:  Med Pediatr Oncol       Date:  1990

6.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

7.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates.

Authors:  W M Hryniuk; J R Bertino
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.